期刊文献+

(3R,4R)-4-叠氮基-3-哌啶醇的合成

Synthesis of (3R,4R)-4-azido-3-piperidinol
下载PDF
导出
摘要 研究了以吡啶和苄氯为起始原料,经五步反应得到抗癌药BMS-690514的关键中间体(3R,4R)-4-叠氮基-3-哌啶醇.反应首先得到N-苄基-1,2,3,6-四氢吡啶,进一步通过氯甲酸乙酯取代、环氧化反应得到7-氧杂-3-氮杂双环[4.1.0]庚烷-3-甲酸乙酯,然后发生叠氮化反应得到构型不同的混合产物,通过手性制备得到(3R,4R)-4-叠氮基-3-羟基-1-哌啶甲酸乙酯,水解该中间产物得到最终产物(3R,4R)-4-叠氮基-3-哌啶醇.该方法使用苄氯反应得到更易离去的苄基离去基团,使产物的收率提高了14.2%;采用与已有手性制备(3R,4R)-4-叠氮基-3-羟基-1-哌啶甲酸乙酯的不同方法,使产物的收率提高了20.2%.所用原材料廉价易得,可有效降低成本. The acquirement of key intermediate (3R, 4R)-4-azido-3-piperidinol of anticancer drug BMS-690514, through five-step reaction is investigated by taking pyridine and benzyl chloride as raw materials. In the reaction, N- benzyl -1,2,3,6- four hydrogen pyridine is obtained. First, Further, 7 - oxa - 3 - azabicyclo[4.1.0]heptane-3-ethyl formate is obtained by substitution of ethyl chloroformate and reaction of epoxidation. Then, the mixed resultants with different types of configuration will be gotten after azide reaction,(3R, 4R)-4-azido base-3-hydroxy-1-piperidine ethyl formate will be obtained by chiral preparation, and final resultant (3R, 4R)-4-azido-3-piperidinol will be gotten to get by hydrolysis of the intermediate resultant. In this method, the benzyl chloride react is used to get a easily departing benzyl-base leaving group, which will increase the yield of the resultant by 14.2%;employment of preparation method of (3R,4R)-ethyl 4-azido-3-hydroxypiperidine-1-carboxylate different from available chiral preparation one will be able to increase the yield of the resultant by 20.2%. Raw materials are cheap and easy to get, and the cost will be effectively reduced.
作者 刘生丽 王晓霞 李卫平 陈文秀 李松芳 刘荣 LIU Sheng-li;WANG Xiao-xia;LI Wei-ping;CHEN Wen-xiu;LI Song-fang;LIU Rong(Key Laboratory of Fine Chemical Engineering of Gansu Province, Lanzhou 730020, China;Gansu Research Institute of Chemical Industry co., ltd, Lanzhou 730020, China)
出处 《兰州理工大学学报》 CAS 北大核心 2019年第3期73-76,共4页 Journal of Lanzhou University of Technology
基金 甘肃省省青年科技基金计划(1506RJYA136) 甘肃省省属科研院所基础条件建设专项(17JR3TA004)
关键词 吡啶 (3R 4R)-4-叠氮基-3-哌啶醇 BMS-690514 合成 pyridine (3R,4R)-4-azido-3-piperidinol BMS-690514 synthesis
  • 相关文献

参考文献3

二级参考文献35

  • 1Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer [ J ]. Semin Oncol, 2006,33 (4): 369-385.
  • 2Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Ireesa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tymsine kinase [J]. Cancer Res, 2002, 62 (9) : 2554-2560.
  • 3Bonomi P. Erlelinib:a new therapeutic, approach for non-small cell lung cancer [J]. Expert Opin Investig Drugs, 2003,12 (8) : 1395-1401.
  • 4Fukuoka M, Yano S, Gisccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib tor previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12) :2237-2246.
  • 5Kris M G, Natale R B, Herbst R S, et al. Effieacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosinc kinase inhibitor, in symptomatic patients with non- small cell lung cancer: a randomized trial [J]. JAMA, 2003, 290(16) :2149-2158.
  • 6Thateher N, Chang A, Parikh P, et al. Gefitinih plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentery study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005,366 (9496): 1527-1537.
  • 7Shepherd F A, Rodrigues Pereira J, Ciuleanu T, et al. Edotinib in previously treated non-small-cell lung cancer [J]. N Eng J Med, 2005,353(2) :123-132.
  • 8Lai C S, Boshoff C, Falzon M, et al. Complete tespouse to erlotinib treatment in brain metastases from recurrent NSCLC [J ]. Thorax, 2006,61 ( 1 ) :91.
  • 9Becker A, van Wijk A, Smit E F, et al. Side-effec, ts of long- term administration of erlotinib in patients with non-small cell lung cancer [J]. J Thorac Oncol, 2010,5(9) : 1477-1480.
  • 10Wu J Y, Wu S G, Yang C H, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations [J ]. Lung Cancer, 2011,72(2) : 205-212.

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部